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OBJECTIVE — Becausemanypatientswithdiabeticmacularedema(DME)donotrespondto
focal/grid laser photocoagulation, the only currently approved treatment, alternatives are
needed.Basedonencouragingpreliminaryﬁndings,weaimedtoassessefﬁcacyandsafetyofthe
anti–tumor necrosis factor (TNF) monoclonal antibody inﬂiximab in this condition.
RESEARCH DESIGN AND METHODS — This was a single-center, double-blind, ran-
domized, placebo-controlled, crossover study. Eleven patients with sight-threatening DME per-
sisting after two sessions of laser photocoagulation received inﬂiximab (5 mg/kg) intravenously
atweeks0,2,6,and14,followedbyplaceboatweeks16,18,22,and30,orviceversa.Blinding
was maintained to week 32, when the ﬁnal assessments were performed. Best corrected visual
acuity evaluated by a mixed-models approach for imbalanced crossover design using the per-
centage difference as the outcome variable was the primary study end point. Data were analyzed
on an intention-to-treat basis.
RESULTS — Early Treatment of Diabetic Retinopathy Study (ETDRS) scores dropped from
31.6  5.1 (mean  SD) letters read at baseline to 28.8  11.6 letters read at week 16 in six
placebo-treatedeyesandimprovedto35.411.2lettersreadafterinﬂiximab.Incontrast,visual
acuity improved from 23.5  10.3 at baseline to 30.4  13.4 letters read at week 16 in eight
inﬂiximab-treated eyes and was sustained at completion of placebo treatment (31.4  12.1
letters read). The excess visual acuity in inﬂiximab-treated eyes was greater by 24.3% compared
with that in placebo-treated eyes (95% CI 4.8–43.7; P  0.017). Inﬂiximab treatment was well
tolerated.
CONCLUSIONS — The positive results of this small phase III study suggest that larger and
longer term trials should be conducted to assess the efﬁcacy of systemic or intravitreal anti-TNF
agent administration for primary treatment of DME.
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D
iabetic macular edema (DME) is a
serious complication of diabetes
and a leading cause of vision loss in
the working-age population of most de-
veloped countries (1,2). Data from the
Wisconsin Epidemiological Study of Dia-
betic Retinopathy estimate that after 15
years of known duration of diabetes, the
prevalence of DME is 20% in patients
withtype1diabetes,25%inpatientswith
type 2 diabetes who are treated with in-
sulin, and 14% in the patients with type 2
diabetes who are not treated with insulin
(3).Apreviousstudyhasshownthat53%
oftheeyeswithDMEinvolvingthecenter
of the macula lost two or three lines of
visual acuity over a 2-year period (4). Fo-
cal/grid laser photocoagulation (two ses-
sions for optimal results) has been the
standard for treatment for DME over the
past two decades. However, this treat-
ment effectively reduces the risk of vision
loss in 50% of patients. Even among
those patients who achieve an initial re-
sponse, recurrences requiring ongoing
treatment are common (1,5). Currently,
there are no approved treatment options
foreyeswithDMErefractorytolaserpho-
tocoagulation (2,6).
Tumor necrosis factor (TNF) is a
pleiotropic cytokine, central to the devel-
opment and homeostasis of the immune
system and a regulator of cell activation,
differentiation, and death. In the past few
decades, there has been an enormous sci-
entiﬁcandclinicalinterestinunderstand-
ingthefunctionofTNFinphysiologyand
disease, and a vast amount of data has
accumulated at the biochemical, molecu-
lar, and cellular levels, establishing TNF
asaprototypeforin-depthunderstanding
ofphysiologicalandpathogenicfunctions
of a cytokine (7). This knowledge primed
the successful development of anti-TNF
therapies in the 1990s. Inﬂiximab (Remi-
cade) is a chimeric monoclonal antibody
speciﬁc for human TNF that has shown
efﬁcacyintreatmentofchronicinﬂamma-
torydiseasesaffectingthejoints,skin,and
gut. Since its ﬁrst launch in 1998,
1,100,000 patients worldwide have
been treated with this drug for approved
indications, including rheumatoid arthri-
tis, ankylosing spondylitis, psoriatic ar-
thritis, plaque psoriasis, and Crohn
disease, including pediatric patients (8).
Inﬂiximab is given intravenously every
4–8 weeks at a dose ranging from 3 to 10
mg/kg and has an acceptable safety
proﬁle.
Several lines of evidence suggest an
inﬂammatory basis for DME (9). Along
this line, treatment modalities have been
tried with variable success. Such treat-
ments include pharmacological therapy
withoralproteinkinaseCinhibitors(10),
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lial growth factor (VEGF) (11), intravit-
real injections of corticosteroids (12,13),
and high doses of nonsteroidal anti-
inﬂammatory drugs that lower retinal ex-
pression of TNF (14). According to our
previously published preliminary results,
a clinically meaningful recovery of useful
vision was achieved after two inﬂiximab
infusions in four of six eyes with severe
diffuse DME (15). Comparable beneﬁcial
results have been obtained in patients
with severe, chronic cystoid macular
edema complicating intermediate uveitis,
Adamantiades-Behc ¸et disease, or adult-
type vascular pseudotumor (16). Re-
peated treatment in one diabetic patient
produced a further signiﬁcant improve-
ment of DME (15), suggesting that the
clinical response to anti-TNF dosing reg-
imens is individualized, as observed in
patients with arthritis (8) or in patients
with uveitic macular edema (16).
Based on the evidence for anti-TNF
treatment in DME and the limitations of
current treatments, we undertook this
phase III study to prospectively investi-
gatetheefﬁcacyandsafetyofinﬂiximabin
the treatment of patients who were in
danger of vision loss due to DME refrac-
tory to laser photocoagulation.
RESEARCH DESIGN AND
METHODS— This is an investiga-
tor-initiated phase III double-blind,
randomized, placebo-controlled, two-
arm crossover clinical study. The study
adhered to the guidelines of the Declara-
tion of Helsinki, and the protocol and
consent form were approved by the local
investigationalreviewboard,theNational
Ethics Committee, and the Ministry of
Health. Each patient provided written in-
formed consent.
Patient eligibility and exclusion
criteria
Patients (aged 18 years) with type 1 or
type 2 diabetes and DME resulting in best
corrected visual acuity (BCVA) of 0.4
were eligible if they had at least two pre-
vious sessions of laser photocoagulation
6 months before enrollment or if they
had leaking microaneurysms within the
foveal avascular zone, making laser pho-
tocoagulation unsafe for the central vi-
sion. In addition to standard inclusion
andexclusioncriteriaforphaseIIIstudies
of inﬂiximab, patients were excluded if
they had 1) vitreoretinal traction, 2) reti-
nal detachment, 3) proliferative diabetic
retinopathy requiring immediate panreti-
nalphotocoagulation,4)anypreviouseye
surgery 6 months before the study, in-
cludinganyintravitrealinfusions,5)mac-
ularedemaoftheischemictypeorcaused
by retinal conditions other than diabetes,
6) cataract or media opacities of a degree
that precluded accurate retinal photo-
graphs or optical coherence tomography
(OCT) measurement, 7) hard exudates
under the fovea, or 8) uncontrolled arte-
rial hypertension (blood pressure 180/
110 mmHg), a major change in glycemic
control (e.g., 2% change in A1C) within
the last 6 months, or a change in daily
number of insulin injections.
Study protocol
Consentingpatientswerescreenedforthe
study within 2 weeks before random as-
signment with a medical history, physical
examination, electrocardiogram, puriﬁed
protein derivative test, chest X-ray, and
laboratory tests including hemoglobin,
A1C, platelet count, white blood cell
count and differential, aspartate amino-
transferase, alanine aminotransferase,
-glutamyl transferase, alkaline phospha-
tase, total and conjugated bilirubin, lac-
tate dehydrogenase, plasma lipids (total
cholesterol, HDL cholesterol, and triglyc-
erides), creatinine phosphokinase, renal
function (urea and creatinine), sodium,
potassium, calcium, phosphate, and se-
rological tests for hepatitis and HIV
infection. In addition, an experienced ex-
aminer obtained ophthalmic/DME his-
tory and performed, in both eyes,
measurements of BCVA, OCT, stereo-
scopicfundusphotographs(sevenﬁelds),
applanation tonometry, and ﬂuorescein
angiography.
Patients were randomly allocated
1:1 to receive placebo or inﬂiximab in a
two-armed crossover, double-blind de-
Table 1—Demographic and disease characteristics of patients with DME and individual
BCVA values of eligible eyes at baseline (week 2), end of study treatment 1 (week 16), and
end of study treatment 2 (week 32)
Patient’s sex, age
(years), diabetes
type, years of
diabetes, A1C (%) Eye
No. of previous
laser treatments,
months since
last session Treatment* Period†
BCVA
baseline BCVA
BCVA
Change
(%)
M, 40, 1, 4, 6.9 01 2, 7 A 1 33 40 21.2
01 B 2 40 47 17.5
M, 67, 2, 27, 7.1 02 0 A 1 40 34 15.0
02 B 2 34 40 17.6
F, 71, 2, 20, 7.0 03 3, 13 A 1 29 34 17.2
03 B 2 34 35 2.9
F, 56, 2, 19, 6.9 04 4, 6 A 1 28 10 64.3
04 B 2 10 17 70.0
05 4, 6 A 1 28 26 7.1
05 B 2 26 38 46.2
M, 64, 2, 4, 5.5 06 4, 12 A 1 40 40 0.0
M, 73, 2, 18, 9.3 07 0 B 1 27 28 3.7
07 A 2 28 26 7.1
F, 63, 2, 19, 7.9 08 2, 12 B 1 6 9 50.0
08 A 2 9 13 44.4
09 2, 8 B 1 10 12 20.0
09 A 2 12 15 25.0
F, 40, 2, 3, 5.4 10 2, 6 B 1 28 31 10.7
10 A 2 31 42 35.5
11 2, 9 B 1 24 39 62.5
11 A 2 39 40 2.6
F, 57, 2, 10, 5.6 12 8, 14 B 1 25 40 60.0
12 A 2 40 33 17.5
M, 71, 2, 11, 8.3 13 2, 6 B 1 35 39 11.4
13 A 2 39 39 0.0
M, 73, 2, 27, 6.8 14 3, 10 B 1 33 45 36.4
14 A 2 45 43 4.4
*A denotes placebo; B denotes inﬂiximab. †Study treatment 1: from baseline to week 16; study treatment 2:
from week 16 to week 32. F, female; M, male.
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domization list generated in SAS. Patients
received placebo at weeks 0, 2, 6, and 14,
followed by inﬂiximab at weeks 16, 18,
22,and30(groupA),orviceversa(group
B) in addition to standard therapy for di-
abetes, hypertension, and dyslipidemia,
which remained unchanged during the
study. All study drugs were administered
via a 2-h intravenous infusion at a dose of
5 mg/kg body wt on the scheduled visits
at weeks 0, 2, 6, 14, 16, 18, 22, and 30.
Blinding was maintained to week 32,
when the ﬁnal clinical, laboratory, and
ophthalmic evaluation was performed in
all patients. Finally, adverse event re-
porting and a complete physical exam-
ination were performed at week 56
(long-term follow-up visit).
PhysicalexaminationandBCVAmea-
surements of the number of letters a pa-
tient was able to read from the Early
Treatment Diabetic Retinopathy study
(ETDRS) charts with correction for indi-
vidual refractive errors were performed at
every visit. Foveal thickness measure-
ments by third-generation OCT (Stratus
OCTIII),usingthefastmacularthickness
scan, stereoscopic fundus photographs
(seven ﬁelds), and intraocular pressure
measurements using a Goldman applana-
tion tonometer were performed at weeks
8, 16, 24, and 32. Hematological/
biochemical tests and ﬂuorescein angio-
grams were performed at weeks 16 and
32. Study physicians were blinded to the
subject’s treatment (inﬂiximab or pla-
cebo) as well as to the subject’s previous
visual acuity assessments.
Outcome measures and statistical
analysis
Theprimaryendpointofthestudywasto
assess the efﬁcacy and safety of four infu-
sionsofinﬂiximabonBCVA,evaluatedby
amixed-modelsapproachforimbalanced
crossover design using the percent differ-
ence between inﬂiximab and placebo
groups as an outcome variable. The sec-
ondary end points were 1) the effect
of inﬂiximab on the anatomic change of
DME,assessedbyOCTand2)theeffectof
inﬂiximab on diabetic retinopathy, as-
sessed by fundus photographs and ﬂu-
oroangiographic studies. Data were
analyzed on an intention-to-treat basis.
The treatment effect of inﬂiximab versus
placebo in macular thickness and fundus
photographsresultswasalsoevaluatedby
amixed-modelsapproachforimbalanced
crossover design using the percent differ-
ence as an outcome variable. The carry-
over effect was also tested in this model.
The residual maximum likelihood tech-
nique was used for estimating variance
components.
The planned sample size of 26 pa-
tients was based on the expected reduc-
tion of BCVA after treatment with
inﬂiximab (16). It was estimated that 22
evaluable eyes (11 per study arm) would
provide 90% power to detect a mean dif-
ference in log minimum angle of resolu-
tion (logMAR) BCVA of 0.67 (equivalent
to 22 letters read in the EDTRS chart) at a
0.001 level of statistical signiﬁcance. Un-
dertheassumptionofa15%dropoutrate,
it was decided to recruit 13 patients for
each treatment sequence. However, the
study was terminated after enrollment of
the ﬁrst 12 patients because of inability to
recruit additional patients who had not
anyintravitrealinfusionwithintheprior6
months (exclusion criterion 4, as de-
scribed above). Statistical analysis was
performed by SAS (version 9.1.3) statisti-
cal software.
RESULTS— Demographic and dis-
ease characteristics of the 11 treated pa-
tients are shown in Table 1. There were
three women and eight men, aged be-
tween 40 and 73 years, with diabetes du-
ration ranging between 3 and 20 years (1
patient with type 1 diabetes and 10 pa-
tients with type 2 diabetes). The addi-
Figure 1—Changes in visual acuity (VA) measured by the number of letters that a patient was
able to read from the ETDRS chart from baseline to study end. Eyes of group A and group B were
treated initially with placebo followed by inﬂiximab or vice versa, respectively (A). The improve-
ment of visual acuity in inﬂiximab-treated eyes is signiﬁcantly greater by 24.3% compared with
that of placebo-treated eyes, as evaluated by a mixed-models approach for imbalanced crossover
design (B).
Sﬁkakis and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 7, JULY 2010 1525tional enrolled patient, aged 72, was
randomly assigned to initially receive pla-
cebo(groupA),buthadanacutemyocar-
dial infarction 2 days before the ﬁrst
scheduled injection and withdrew from
thestudy.OnepatientfromgroupAwith-
drew consent at week 18 after receiving
fourplaceboinjectionsandtheﬁrstinﬂix-
imab injection. In total 14 eyes were eli-
gible for analysis (6 eyes in group A,
including this patient’s response to pla-
cebo treatment, and 8 eyes in group B)
(Table 1).
Primary study objective: changes in
best corrected visual acuity
Individual values of BCVA at baseline,
week16(endoftheﬁrststudytreatment),
and week 32 (ﬁnal evaluation after the
second study treatment) are shown in Ta-
ble 1. Baseline BCVA was not different
between groups (31.6  5.1 vs. 23.5 
10.3 letters read; t  1.7; P  0.10). As
shown in Fig. 1A, BCVA decreased from
31.6  5.1 at baseline to 28.8  11.6
letters read at week 16 in eyes treated ini-
tially with placebo and subsequently in-
creased to 35.4  11.2 letters read at
completionofinﬂiximabtreatment(week
32). On the other hand, BCVA increased
from 23.5  10.3 at baseline to 30.4 
13.4lettersreadatweek16ineyestreated
initially with inﬂiximab and remained es-
sentially unchanged at completion of pla-
cebo treatment (31.4  12.1 letters read,
week 32).
Collectively, four infusions of inﬂix-
imab resulted in an increase in BCVA,
from mean  SD 25.5  10.7 (range
6–40) to 32.3  12.4 (range 9–47) let-
ters read (n  13). In contrast, BCVA re-
mainedessentiallyunchangedinplacebo-
treated eyes (n  14), from 31.5  10.5
(range 9–45) to 31.1  11.3 (range 10–
43) letters read. Least squares means in-
dicated that inﬂiximab administration
resulted in 28.6% and placebo resulted in
4.3% improvement in visual acuity. A
possible carryover effect of inﬂiximab in
the second part of the study was tested in
this model and was found to be nonsig-
niﬁcant. Overall, the improvement in
visual acuity in the inﬂiximab-treated
eyes was signiﬁcantly greater by 24.3%
compared with that in placebo-treated
eyes (95% CI 4.8–43.7; P  0.0167)
(Fig. 1B).
Secondary anatomic and vision-
related objectives
A similar analysis failed to reveal a signif-
icant effect of inﬂiximab over placebo in
the secondary end points of the study.
Leastsquaresmeansindicatedthatcentral
macular thickness assessed by OCT de-
creased by 3.7% with inﬂiximab and in-
creased by 1.3% with placebo (P  0.5).
Moreover, no signiﬁcant difference be-
tween inﬂiximab and placebo could be
demonstrated in the scores of fundus
photographs graded according to the
ETDRS protocol.
Baseline versus 32-week evaluation
measurements
As shown in Table 2, the following
changes from baseline (2 week) to the
end of the study (32 weeks) were evident
inour10patients(13eyes)who,eitherin
the ﬁrst or second part of the study, re-
ceived four inﬂiximab infusions: BCVA
improved by at least one line (5 letters in
the EDTRS chart) in 10 of 14 eyes (77%),
whereas5eyes(38%)gainedtwoormore
lines, 2 eyes remained stable, and 1 eye
worsened by 5 letters. Foveal thickness
decreased by 10% in 5 eyes (38%), re-
mained stable in 5 eyes, and increased by
10% in 3 eyes. Finally, as documented
by both fundus photographs and ﬂuoro-
angiography, the status of diabetic reti-
nopathy improved in 3 eyes, remained
stable in 5 eyes, and deteriorated in 1 eye.
Fundus photographs and ﬂuoroangiogra-
phy yielded conﬂicting results in the re-
maining 4 eyes.
Safety issues
Inﬂiximab was well tolerated and no
safety issues emerged from hematologic
monitoring, urinalysis, or ophthalmic as-
sessments, including intraocular pressure
or cataract formation during the study.
Moreover, no signiﬁcant impact of pla-
cebo or inﬂiximab on glycemic control
was noted. One male patient (aged 64,
with diabetes type 2 for 4 years; Table 1)
had a diagnosis of breast cancer 5 months
after the baseline evaluation. This condi-
tion was considered to be unrelated to in-
ﬂiximab treatment, because a slightly
palpable mass leading to the ﬁnal diagno-
siswasrevealedinaphysicalexamination
at week 18, only 14 days after the ﬁrst
inﬂiximab injection. Another male pa-
tient (aged 73, with diabetes type 2 for 18
years; Table 1) developed an upper respi-
ratory tract infection that was treated suc-
cessfullywithantibioticsatweek29while
receiving placebo. Finally, one male pa-
tient (aged 71, with diabetes type 2 for 11
years; Table 1) developed a neuro-
ischemic foot ulcer at week 51 (18 weeks
after receiving the eighth study injection
of placebo).
CONCLUSIONS — Evidence sug-
gests that altered local expression of TNF
may play an important role in the patho-
genesis of DME (17,18) and that low-
grade subclinical inﬂammation is
responsible for many of the signature vas-
cular lesions of diabetic retinopathy (9).
Moreover, studies in patients with arthri-
tis have shown that anti-TNF therapy
negatively affects vascular permeability
and angiogenesis by decreasing VEGF
(19), which has been implicated directly
Table 2—Changes from baseline to 32 weeks in BCVA, DME, and retinopathy status after
inﬂiximab, given either during study treatment 1 (eyes 01–05) or study treatment 2 (eyes
07–14)
Eye
Difference in letters
read (% BCVA change)
% DME thickness
change
Fundus
photographs* Fluoroangiography
01 13 (42) 30 35 to 35 Worst
02 0 (0) 7 35 to 35 Stable
03 6 (21) 15 20 to 35 Stable
04 9( 39) 7 53 to 53 Stable
05 10 (36) 14 43 to 43 Stable
07 1( 4) 16 35 to 20 Improved
08 7 (117) 45 53 to 53 Stable
09 5 (50) 6 47 to 47 Stable
10 14 (50) 20 43 to 35 Improved
11 14 (67) 15 35 to 35 Improved
12 8 (32) 6 53 to 43 Worst
13 4 (11) 2 35 to 47 Worst
14 10 (30) 20 35 to 20 Improved
*Grading according to the ETDRS protocol: 20: macular edema only; 35, 43, 47, and 53: mild, moderate,
moderately severe, and severe nonproliferative diabetic retinopathy, respectively.
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retinopathy (2,9,11). Although studies
have shown the possible beneﬁts of intra-
vitreal corticosteroids and anti-VEGF an-
tibodies in the treatment of DME, focal/
grid laser photocoagulation continues to
betheonlyprovensafeandeffectivetreat-
ment (2). Still, this treatment targets only
advanced stages of the disease. It is note-
worthy that there are no previous ran-
domized placebo-controlled phase III
studies for any treatment option in DME.
The present study included patients
with sight-threatening DME that was un-
manageable by laser photocoagulation.
Of the 14 evaluable eyes, 12 had previ-
ously received at least two laser sessions
(maximum eight sessions, eye 12) (Table
1). The two remaining eyes had leaking
microaneurysms within the foveal avas-
cular zone, making laser photocoagula-
tion unsafe for the central vision. In view
of our previously published encouraging
preliminary results with inﬂiximab (15),
the crossover design of this phase III
study was chosen to allow all participants
with sight-threatening DME to receive in-
ﬂiximab and to enhance the statistical
power of the study.
Because of the strict study exclusion
criteria and because intravitreal adminis-
tration of anti-VEGF agents has been in-
creasingly used over the past 2 years in
Greece, we were able to recruit only 12
patients. Thus, the main limitation of the
present study is the small sample size,
limiting statistical analysis and not ensur-
ing that randomization balanced all
known and unknown risk factors be-
tween groups. However, the mean dura-
tion of diabetes, as well as the mean
number of previous laser treatments and
length of time since the last session were
similar (Table 1), whereas baseline BCVA
was also not different between groups.
Despite the small sample size, our short
crossover trial of a conventional dose of
inﬂiximab demonstrated a signiﬁcant im-
provement over placebo on the severely
impaired visual acuity of these patients.
Inﬂiximab,eitherasaﬁrstorsecondagent
resulted in almost similar increases in
BCVA (6.9 and 6.6 mean letters read,
respectively). Thus, this inﬂiximab-
induced mean observed improvement of
almost7lettersreadintheEDTRSchartis
comparabletothemeangaininBCVAat6
monthsinpatientswithDMEtreatedwith
four intravitreal injections of the anti-
VEGFagentranibizumab(11).Moreover,
attheendofthestudyBCVAimprovedby
atleastonelinein77%andbyatleasttwo
lines in 38% of inﬂiximab-treated eyes.
Theseresultsareconsideredclinicallyim-
portant, given the fact that patients in-
cluded in this study were unsuitable for
all available approved treatment options.
It seems that improvement of BCVA was
not correlated with the secondary ana-
tomic and vision-related end points, be-
cause neither an anatomic improvement
of DME by OCT nor a decrease in fundus
photographs grading by the ETDRS pro-
tocol could be demonstrated. A recent
studyof323eyesfromarandomizedclin-
ical trial of two methods of laser photoco-
agulation for DME found that the OCT-
based assessment of the extensiveness of
DMEneitherexplainsadditionalvariation
in baseline visual acuity above that ex-
plained by other known important vari-
ables nor predicts changes in macular
thickness or visual acuity after laser pho-
tocoagulation (20). It is possible that
other inﬂiximab-related changes may ac-
count for our ﬁndings. For example, local
TNF neutralization by inﬂiximab could
have exerted a beneﬁcial effect on photo-
Figure2—SequentialOCTimagesatbaseline(A),atcompletionofplacebotreatment(B),andat
completionofinﬂiximabtreatment(C).Thephotoreceptorinner/outersegmentjunctionlineatthe
foveola is highly disrupted at week 2( A, arrow), becomes almost absent at week 16 (B, arrow),
and appears partially restored at week 32 (C, arrow).
Sﬁkakis and Associates
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improvement in BCVA despite the persis-
tence of macular edema in patients
throughout our study. Interestingly, as
shown in Fig. 2, the photoreceptor inner/
outer segment line, which was invisible at
baseline or after the placebo treatment,
partiallyreappearedafterinﬂiximabtreat-
ment.Whethersuchchangesunderliethe
inﬂiximab-induced BCVA improvement
remains to be seen, because the photore-
ceptor inner/outer segment junction line
wasnotidentiﬁablebyOCTatanytimein
all other patients.
The key safety considerations that
emerged during the ﬁrst years of clinical
use of inﬂiximab included infections, au-
toimmune disease, demyelinating dis-
ease, malignancies, and congestive heart
failure (8). Overall rates of these condi-
tionsinrandomizedcontrolledtrialswere
not signiﬁcantly increased during treat-
ment compared with placebo. Postmar-
keting surveillance data in thousands of
patientshaveclearlyshownthatthesafety
proﬁleofinﬂiximabisexcellent,provided
that it is not used to treat patients with
active infection, malignancy, preexist-
ingdemyelinatingconditions,andheart
failure and that precautions are taken
for reactivation of latent tuberculosis.
No other particular safety signals in pa-
tients with diabetes have emerged (8).
Overall, inﬂiximab was well tolerated in
our study.
To summarize, a short-term treat-
ment with inﬂiximab signiﬁcantly im-
proved BCVA in eyes with advanced-
stage sight-threatening DME refractory to
standard treatment, further suggesting an
important role for TNF-mediated patho-
genetic mechanisms in this condition.
This positive result also suggests that
largerandlongertermplacebo-controlled
trials are warranted to assess the efﬁcacy
and safety of systemic TNF blockade
and/or of local delivery of anti-TNF anti-
bodies by intravitreal injection (21–24)
for the primary treatment of DME.
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